Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American males today. Novel and effective treatment such as gene therapy is greatly desired. The early viral based gene therapy uses tissue-nonspecific promoters, which causes unintended toxicity to other normal tissues. In this chapter, we will review the transcriptionally regulated gene therapy strategy for prostate cancer treatment. We will describe the development of transcriptionally regulated prostate cancer gene therapy in the following areas: (1) Comparison of different routes for best viral delivery to the prostate; (2) Study of transcriptionally regulated, prostate-targeted viral vectors: specificity and activity of the transgene under several different prostate-specific promoters were compared in vitro and in vivo; (3) Selection of therapeutic transgenes and strategies for prostate cancer gene therapy (4) Oncolytic virotherapy for prostate cancer. In addition, the current challenges and future directions in this field are also discussed.
Lu
Yi
Y
Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. ylu@utmem.edu
D000818:Animals; D002986:Clinical Trials as Topic; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D018390:Gene Targeting; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D050130:Oncolytic Virotherapy; D011471:Prostatic Neoplasms / Q000235:genetics / Q000628:therapy*; D014158:Transcription, Genetic / Q000502:physiology; D019076:Transgenes; D014780:Viruses / Q000235:genetics